US Stock Insider Trading | Scholar Rock Holding Discloses 1 Insider Transaction on February 6

K-LinePoet · 2026-03-07T02:43:03+00:00

Scholar Rock Holding (SRRK) recently disclosed insider trading activity, with more than 10% shareholder Invus Global purchasing 1.575 million shares in December 2025. Additionally, executives such as Qatanani Mo frequently sold shares in January 2026. The company focuses on developing innovative drugs to treat serious diseases.

K-LinePoet

2026-03-07 02:43:03

Abstract generation in progress

On February 6, 2026, Scholar Rock Holding (SRRK) disclosed a company insider transaction. Shareholder with over 10% ownership, Invus Global Management, LLC, purchased 1,575,000 shares on December 11, 2025.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Shareholder with over 10%	Invus Global Management, LLC	December 11, 2025	Buy	1,575,000	7.35	11,576,300
January 23, 2026	Executive	Qatanani Mo	January 22, 2026	Sell	12,800	46.85	598,720
January 23, 2026	Executive	Qatanani Mo	January 22, 2026	Sell	2,119	45.87	97,150
January 21, 2026	Executive	Qatanani Mo	January 16, 2026	Sell	8,406	44.48	374,300
January 21, 2026	Executive	Ho Junlin	January 16, 2026	Sell	8,016	44.48	356,600
January 21, 2026	Executive	Marantz Jing L.	January 16, 2026	Sell	5,798	44.48	257,900
January 21, 2026	Executive	Parlavecchio Caryn	January 16, 2026	Sell	6,600	44.48	293,600
January 16, 2026	Executive	Qatanani Mo	January 14, 2026	Buy	1,407	18.08	25,400
January 16, 2026	Executive	Qatanani Mo	January 14, 2026	Buy	321	7.62	2,446
January 16, 2026	Executive	Qatanani Mo	January 14, 2026	Buy	5,893	15.75	92,800

【Company Profile】

Scholar Rock Holding Corporation was founded in 2017 in Delaware. The company is a biopharmaceutical firm focused on discovering and developing innovative drugs for treating serious diseases, where protein growth factor signaling plays a key role. As a global leader in transforming growth factor beta superfamily biology, the company’s new understanding of growth factor-activated molecular mechanisms enables it to develop a proprietary platform for discovering and developing monoclonal antibodies targeting growth factor precursors or their potential forms locally and selectively. Based on this proprietary and scalable technology platform, the company is building a growing pipeline of new candidate products aimed at changing the lives of patients with various serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-limited anemia.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes